IMR Press / RCM / Special Issues / lipids_cv_risk

Lipids and Cardiovascular Risks

Submission deadline: 30 August 2022
Special Issue Editors
  • Federica Fogacci
    Hypertension and Cardiovascular Risk Factors Research Group, Medical and Surgical Sciences Department, University of Bologna, Bologna, Italy
    Interests: lipids; emerging lipid-lowering agents; hypertension; vascular aging
  • Giuliano Tocci, MD, PhD
    Hypertension Unit, Division of Cardiology, Department of Clinical and Molecular Medicine, University of Rome Sapienza, Sant'Andrea Hospital, Rome, Italy
    Interests: hypertension; vascular aging; lipids; cardiovascular risk
  • Arrigo F.G. Cicero, MD, PhD
    Hypertension and Cardiovascular Risk Factors Research Group, Medical and Surgical Sciences Department, University of Bologna, Bologna, Italy
    Interests: hypertension; lipid; vascular aging; diet; nutraceuticals
Special Issue Information

Dear Colleagues,

Lipids and lipoprotein particles crucially contribute to atherosclerosis as underlying pathology of cardiovascular disease; they influence inflammatory processes as well as the function of leukocytes, vascular and cardiac cells, thereby affecting vessels and the heart.
High serum levels of cholesterol are a major risk factor for the development of cardiovascular diseases that are in turn the leading cause of death and disability in developed countries. Statins are the recommended first line treatment for hypercholesterolemia, with their ability to decrease LDL-C by 30-50% and proportionally reduce the risk of cardiovascular events. Unfortunately, their application may prove insufficient to achieve LDL-C goals, while intensive treatment is not always well tolerated by patients. In addition to LDL-C, other serum lipid fractions such as fatty acids, HDL-C, lipoprotein(a) may also increase individual cardiovascular risk.

In response to the need for a more personalized approach in the management of dyslipidemia, new injectable lipid-lowering drugs (e.g. PCSK9 inhibitors and small interfering RNA therapy) have recently been developed, with promising results thus far.

This Special Issue aims to collect high-quality original articles and comprehensive reviews on lipids and cardiovascular disease. Topics of interest include but are not limited to data from epidemiological studies and evidence regarding traditional and emerging lipid-lowering drugs.

Dr. Federica Fogacci, Asst. Prof. Giuliano Tocci and Assoc. Prof.Arrigo F.G. Cicero

Guest Editors

Keywords
lipids
epidemiology
emerging lipid-lowering agents
PCSK9
inclisiran
vascular aging
cardiovascular risk
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2200 USD. Submitted manuscripts should be well formatted in good English.

Back to top